Plasmodium vivax is geographically the most widely distributed cause of malaria in people,
with up to 2· 5 billion people at risk and an estimated 80 million to 300 million clinical cases …

Plasmodium vivax threatens almost 40% of the world's population, resulting in 132-391
million clinical infections each year. Most of these cases originate from South East Asia and …

New developments in Plasmodium vivax malaria: severe disease... : Current Opinion in
Infectious Diseases New developments in Plasmodium vivax malaria: severe disease and the …

The widespread distribution and relapsing nature of Plasmodium vivax infection present
major challenges for the elimination of malaria. To characterize the genetic diversity of this …

OBJECT Chloroquine (CQ) is a quinoline-based drug widely used for the prevention and
treatment of malaria. More recent studies have provided evidence that this drug may also …

The gravity of the threat posed by vivax malaria to public health has been poorly
appreciated. The widely held misperception of Plasmodium vivax as being relatively …

Approximately 230 million people live in Indonesia. The country is also home to over 20
anopheline vectors of malaria which transmit all four of the species of Plasmodium that …

With the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, the middle
east respiratory syndrome CoV (MERS-CoV) in 2012 and the recently discovered SARS …

Introduction: Relapses are important contributors to illness and morbidity in Plasmodium
vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required …

Early parasitological diagnosis and treatment with artemisinin-based combination therapies
(ACTs) are key components of worldwide malaria elimination programmes. In general, use …